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Executive Summary 
   
  Malignant brain gliomas are almost always fatal, with a five year survival rate of only 
3%. This is due in part to the difficulty of treating tumors chemically or surgically. They are 
often deep within the brain, where drugs cannot easily diffusive due to the blood-brain barrier 
and where surgery could be deadly. Emerging techniques for improved treatment include direct 
infusion of treatment drugs, like Paclitaxel, into the tumor in a procedure known as convection-
enhanced drug delivery. These procedures require days of carefully monitored infusion to ensure 
tumor destruction while preserving surrounding tissue. To better understand the drug distribution 
and dosing options for different tumor sizes without dangerous medical tests, we have modeled 
the drug distribution within the tumor and surrounding tissue computationally. The model shows 
drug distributions consistent with current clinical results after a five day procedure. This model 
could now be used to better define dosing levels and procedure parameters to maximize tumor 
removal while preserving healthy tissue in individually unique cases. 
 
Introduction 
 
Background Information 
 
Approximately 200,000 people worldwide are diagnosed with a primary malignant brain 
tumor each year (1), with about 15,000 cases occurring in the United States (2). Despite the 
relative rarity of these tumors,  they account  for a disproportionate number of cancer-related 
deaths (2). Overall, the five year survival rate following a diagnosis with a primary malignant 
brain tumor is roughly 30% (3) and certain types are even more deadly, with a five year survival 
rates close to 3% (4).  
Primary brain tumors are tumors that originate in the brain (2). This is in direct contrast 
with  metastatic  tumors,  which  are  the  result  of  the  spread  to  the  brain  of  cancerous  cells 
originating elsewhere in the body. The most common type of primary brain tumors are malignant 
brain gliomas (2). Gliomas arise from glial cells and can either be malignant or benign (3). The 
malignancy of gliomas is characterized into grades that are based on the tendency for the tumor 
to spread, the tumor’s growth rate and its similarities to normal cells (3). With each specific type     4 
 
of  tumor,  the  grade  varies.  Often,  tumors  contain  various  cells  of  different  grades  (3).  The 
grading system is useful because treatment and prognosis depend on the type of tumor and the 
grade (3).  
The  current  treatments  rely  on  radiation  therapy,  chemotherapy,  surgery,  steroids, 
immunotherapy, and the use of cancer treatment drugs (3). Many neurologists will actually use a 
combination  of  these  therapies  to  treat  a  tumor.  However,  there  are  problems  with  these 
therapies, including the high precision and sophisticated instruments required for surgery, the 
difficulty in delivering drugs across the blood-brain barrier and the troublesome side effects that 
can arise from damaging the brain (3). Because of these issues, these treatments tend to be less 
successful than similar treatments for solid tumor cases located in other parts of the body (2). 
Thus, a better treatment option is necessary. 
One such option is the use of convection-enhanced drug delivery. By use of a positive 
pressure system, this method combats the rapid post-resection recurrence, which many relate to 
the low survival rate of patients with malignant gliomas (4). Convection-enhanced drug delivery 
lends  itself  to  locally  target  the  tumor  by  direct  infusion  of  cancer  treatment  drugs  such  as 
Paclitaxel. This could result in improved clinical outcomes as the procedure limits the exposure 
of the surrounding healthy tissue to the toxic drugs while maximizing drug concentration within 
the tumor (4). The delivery system uses an implanted catheter to deliver drugs infused by a 
pump, as illustrated in Figure 1.  
 
Figure 1. Diagram of convection-enhanced drug delivery system (4)     5 
 
Clinical  trials  have  showed  improved  results  using  this  treatment.  Brain  gliomas, 
however, vary in size (5) and the procedural parameters do not take variability well enough into 
account. A mathematical model of the drug delivery could offer better tailoring of this procedure 
to individual cases by providing ideal dosing to eliminate the tumor while avoiding necrosis of 
surrounding healthy gray matter. 
 
Design Objectives 
 
The primary objective for this design is to provide an experimentally validated COMSOL 
model of convection enhanced drug delivery that can be optimized to kill the tumor but preserve 
healthy tissue. More specifically, this design is to provide a reasonably accurate mathematical 
model  to  better  understand  the  drug  distribution  of  this  5-day  long  process  and  guide  the 
individualization  of  the  medical  procedure  parameters,  such  as  procedure  time,  Paclitaxel 
infusion concentration and pressure for variations between patients. 
 
Problem Schematic 
 
To implement convection-enhanced drug delivery into a tumor as a COMSOL model, we 
first had to consider an appropriate geometry. We assumed the tumor was essentially spherical in 
shape, extracting values for its size from the literature. Since the tumor size values from the 
literature  were  rather  small  relative  to  the  amount  of  surrounding  healthy  tissue,  it  was 
reasonable to assume a semi-infinite geometry. That is, the surrounding healthy tissue is taken in 
COMSOL to be just large enough that it provides the same drug concentration profile as a model 
with a larger healthy tissue radius. These concentric spheres of tumor and healthy tissue have a 
catheter going down their vertical axis to their center. The symmetry in this geometry along this 
vertical axis allows us to simplify the geometry into a half circle, as shown in Figure 2.     6 
 
 
Figure 2. Model Schematic. 2-D Axisymetric  
schematic used for mathematical modeling. (not to scale) 
 
Results and Discussion 
 
  We modeled the distribution of Paclitaxel using the schematic provided above and the 
properties  listed  in  Appendix  A  obtained  from  literary  accounts  of  real  medical  procedures. 
These parameters, including tissue properties and boundary conditions, were used to solve the 
mass  transfer  and  fluid  flow  equations  also  listed  in  Appendix  A  using  COMSOL  over  an 
appropriate mesh described in Appendix B. A solution for the drug concentration profile after the 
5-day procedure was obtained. 
  Initially, to better understand the individual contributions of convection and diffusion in 
the final solution, we obtained uncoupled solutions for mass transfer and fluid flow. A close up 
of the velocity profile obtained from the fluid flow model and the concentration profile obtained 
from the diffusion only model are shown in Figure 3 and Figure 4, respectively. Neither seems to 
have a significant impact far from the catheter tip. This shows that the coupling of the two 
factors is required for an accurate model, and that both contribute to the distribution of the drug 
throughout the brain. 
     7 
 
 
Figure 3: Fluid Flow Model. The velocity profile of the solution obtained from only the fluid 
flow portion of the model. 
 
 
Figure 4: The concentration profile from the diffusion only model. 
 
  Figure 5 below shows the drug concentration in the tumor and surrounding tissue after 5 
days  with  mass  transfer  and  fluid  flow  coupled  through  the  convection  term.  The  drug     8 
 
concentration is highest near the catheter tip, reaching a value of 639 M (infusion concentration) 
and effectively zero in the surrounding tissue. This drug distribution is much more extensive than 
was  suggested  by  each  of  the  uncoupled  solutions.  Literature  values  place  the  toxicity  of 
Paclitaxel around 280 nM (6). Using this value, Figure 6 was obtained, showing the projected 
tissue necrosis in red where the concentration had reached or exceeded the toxicity value. The 
boundary between the tumor and healthy tissue is shown as a solid black line. 
 
   
Figure 5: Concentration Profile. Drug    Figure 6: Expected Necrosis. Red portion  
distribution after 5 days of infusion.      has reached toxic concentrations. 
 
  It  is  clear  from  the  uncoupled  and  coupled  results  of  diffusion  and  convection  that 
convection plays an important role in the dispersion of drug throughout the tissue. To better 
measure this significance, the drug concentration along a radial line from the catheter tip to outer 
tissue boundary was  measured in  the uncoupled (diffusion only) and coupled (diffusion and 
convection) models. This collected data, presented in Figure 7 below, shows the increase in     9 
 
distance of travel of the drug when convection is included, verifying the important role of the 
infusion pressure in the procedure. 
 
 
Figure 7: Comparison of Uncoupled and Coupled Results. Concentration profile 
along radial line with diffusion only (blue line) and with convection (red line). 
 
To validate these results, the plot of expected necrosis above in Figure 6 was compared 
with medical procedure results of similar conditions (6). This had to suffice as validation because 
there  was  no  literature  available  reporting  the  extent  of  healthy  tissue  damage  or  the  drug 
distribution profile after the procedure. The fact that the tumor was completely removed in both 
cases, however, does provide some important validation. In addition to validation of the results, 
mesh convergence was also performed, the results of which are available in Appendix B. 
  This computational solution can be used to optimize the medical procedure to further 
achieve the design objectives. The concentration along a radial line extending from the catheter 
tip to the outer geometry boundary was used again, and the distance along this line at which 
necrosis had extended was measured. This measurement was made at several stored solution 
times to produce the plot in Figure 8 below. This plot shows the extent of necrosis from the 
catheter tip as a function of procedure time and could be used by a physician to tailor a procedure 
time given a discovered tumor size. 
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Figure 8: Optimization of Procedure for Specific Tumor Size. This figure shows 
the necrosis distance from catheter tip during the procedure. 
 
Sensitivity Analysis 
 
  We encountered some difficulty in locating literature values for some of the properties. 
The properties with the most variation between sources and in which we had the least confidence 
were  the  tissue  permeability,  tumor  permeability  and  porosity  (considered  equal  in  both  the 
tumor and tissue). To better understand the effect of these parameters on the solution obtained, 
we performed sensitivity  analysis. We varied these three parameters independently and then 
calculated the average drug concentration within the tumor and compared this average value to 
the  average  of  the  original.  The  individual  sensitivity  analysis  results  for  each  of  tumor 
permeability, tissue permeability and porosity are displayed below in Figures 9, 10, and 11, 
respectively. 
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Figure 9: Tumor Perm. Sensitivity.    Figure 10: Tissue Perm. Sensitivity 
Results of sensitivity analysis on tumor  Results of sensitivity analysis on tissue 
permeability.          permeability. 
 
 
Figure 11: Porosity Sensitivty. Results of sensitivity 
Analysis on permeability of tumor and tissue. 
 
  The  results  of  this  sensitivity  analysis  suggest  a  linear  relationship  between  tumor 
permeability and average tumor concentration, but a higher order relationship between the other 
two parameters. To compare the significance of a 20% variation of each parameter from the true 
value, the plot in Figure 12 was derived. This plot shows the change in average tumor drug 
concentration over a +20% to -20% variation of each parameter. This graph demonstrates that 
variation in the value used for the tumor permeability would have the greatest impact on the 
resulting  solution  compared  to  the  other  uncertain  values.  Thus  additional  research  was 
performed to support the value used. 
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Figure 12: Sensitivity Comparison. Comparison of 
Sensitivity of solution on each of the three parameters. 
 
Conclusion and Design Recommendations 
 
  Using COMSOL, we were able to model the distribution of Paclitaxel in a malignant 
glioma surrounded by healthy tissue delivered via convection-enhanced drug delivery. Using this 
model,  we  were  able  to  optimize  the  combination  of  infusion  pressure,  infused  drug 
concentration, and injection time to kill a maximal amount of malignant glioma cells and a 
minimal  amount  of  healthy  brain  tissue.  Using  an  infusion  pressure  of  666Pa,  initial  drug 
concentration of 639 M, and an injection time of 5 days, we were able to achieve a Paclitaxel 
concentration exceeding 280nM, the lethal concentration for tumor cells, in the entire tumor, 
while limiting the lethal concentration in the surrounding healthy tissue to a small radius. This 
result is supported by medical procedures which removed similar sized tumors using the same 
parameters.  
Our model also illustrates the efficacy of the convection-enhanced drug delivery method, 
displaying the minimal drug distribution achieved by diffusion alone compared to the full tumor 
distribution achieved when coupled with fluid flow. The parameter that has the greatest effect on 
average Paclitaxel concentration in the tumor is tumor permeability, as a sensitivity analysis 
revealed a linear relationship between tumor permeability and average Paclitaxel concentration 
in  the  tumor.  This  could  have  serious  implications  for  clinical  use  of  this  model  to  predict 
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procedural results, as tumor permeability is a parameter that can significantly vary both from 
tumor to tumor as well as within a single tumor. 
Using this model, physicians could better tailor specific dosing of infusion Paclitaxel 
concentration,  infusion  pressure  and  procedure  time  to  individual  tumor  sizes  and  even 
geometries. These benefits come without the dangers of medical trials with such an extreme 
procedure as the one required. 
 
Design Recommendations 
 
These results show that our computational model accurately describes the results of the 
convection-enhanced medical procedure. Doctors and drug companies could use this or a similar 
model to better describe dosing, infusion pressure and procedure time to limit the destruction of 
viable tissue. It could also be used to reduce the amount of time required for such an invasive 
infusion by optimizing other parameters, notably infusion concentration. In some procedures 
with larger or more complex tumors, multiple catheters are required. In these cases a 3D model 
obtained from CAT scans could be used to allow calculation of clinical parameters from the 
computational  model  to  maximize tumor  necrosis.  To  reduce  invasiveness,  smaller  catheters 
could also be used with the model, again, to optimize other parameters to allow for this change. 
The procedure is  so extreme, that the  results  of this  computational  model  could  be used to 
redesign these parameters to make it less invasive while still providing life saving results. 
 
Realistic Constraints 
 
The characteristics of convection-enhanced drug delivery that detract from its practicality 
are the invasiveness and significant injection times required for acceptable drug distribution. The 
procedure requires that the catheter is inserted directly into the center of the tumor. This requires 
a section of the skull to be removed to gain access to the brain, as well as insertion of the catheter 
through healthy brain tissue to reach the tumor. This drastically reduces the practicality of the 
process for tumors located deep in the brain tissue, as it increases the probability of injury to 
brain tissue during the insertion.      14 
 
Perhaps the greatest limiting factor of this treatment becoming a primary option for brain 
tumors is the amount of time the process takes. Our model requires an injection time of 5 days to 
achieve the desired lethal concentration of Paclitaxel throughout the entire tumor. Under our 
conditions, the patient would have to remain stationary with a catheter in his/her brain for 5 days 
straight  which  is  highly  impractical.  Patients  receiving  this  treatment  in  clinical  trials 
occasionally are treated using multiple injection sessions of up to 6 hours spaced out over a 
number of days, but the time in between injections likely decreases the distributive effects of the 
convection.  Increasing  the  injected  drug  concentration  is  certainly  a  possibility,  but  with  an 
increased drug concentration there is an increased risk of exceeding toxic drug concentration 
outside of the tumor in the brain tissue, killing healthy cells. The results of our model reveal a 
promising  future  for  convection-enhanced  drug  delivery  as  both  a  primary  and  adjuvant 
treatment for malignant brain gliomas, but until the aforementioned limitations are addressed in 
clinical trials there is still much research to be done on the process. 
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Appendix A: Mathematical Formulation 
 
  For this model, we used COMSOL to solve coupled governing equations: that for mass 
transfer, and the equations for fluid flow. These governing equations solved are given in the 
following set of equations. 
 
  Mass transfer in either tissue in cylindrical coordinates (2D axi-symmetric): 
 
     
   
Fluid Flow Equation: 
    For r: 
 
 
 
For z 
 
 
  The boundary conditions and initial conditions used in this model are provided in Table 1 
below. 
  Variable  Value 
Diffusion 
Initial tumor concentration  ctumor(t=0)  0 
Initial tissue concentration  ctissue(t=0)  0 
Concentration at catheter tip  Ccathter tip  Constant 639 M 
(infusion conc.) 
Concentration at infinity 
(outer tissue boundary) 
c∞  0 
Flux at catheter wall  N  0 
Flux at line of symmetry  N  0 
Fluid Flow 
Initial x-velocity throughout  ux(t=0)  0 
Initial y-velocity throughout  uy(t=0)  0 
Initial z-velocity throghout  uz(t=0)  0 
Cathode Infusion Pressure  Pcathode tip  Constant 666 Pa 
Pressure at infinity (outer 
tissue boundary) 
P∞  0 
Velocity at catheter wall  ucatheter  0 (no slip)     16 
 
Table 1: Initial and Boundary Conditions 
 
  The subdomain and other properties used in the model were obtained from a number of 
different sources and are available in Table 2 below. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
    Table 2: Model Properties. Properties used in this model, their 
    Symbol used, value and source 
   
Property  Symbol  Value  Units  Source 
Tumor Density  p_u  1050  kg/m
3  (7) 
Tissue Density   P_i  1050  kg/m
3  (8) 
Tumor Diffusivity   D_u  4.16E-7  cm
2/s  (7) 
Tissue Diffusivity   D_i  2.0E-7  cm
2/s  (7) 
Drug Concentration 
(Paclitaxel)  
C  6.39E-4  Moles/ L of saline  (9) 
Infusion Pressure at Tip   P  666  Pa  (10) 
Tumor Radius   r_u  2  cm  (5) 
Tissue Radius (tested 
large enough) 
r_i  6  cm   
Catheter Radius   r_c  0.0114  cm  (11) 
Hydraulic Conductivity of 
Tumor  
k_u  1.65E-
11 
m
3*s/kg  (11) 
Hydraulic Conductivity of 
Tissue  
k_i  5E-12  m
3*s/kg  (10) 
Infusion density (approx. 
water) 
p  1000  kg/m
3   
Infusion Flow Rate   Q  8.33E-5  cm
3/s  (10) 
Dynamic Viscosity   µ  0.89E-3  Pa*s  (12) 
Tissue Porosity   e_i  0.21    (12) 
Paclitaxel Toxicity   Tx  280  nM  (6)     17 
 
Appendix B: Solution Strategy 
 
  To obtain a solution to this model using COMSOL, the multiphysics functionality was 
used. It was used to couple the solution of the fluid flow equation into the mass transfer 
calculations via the convection term. Hence subdomain properties, boundary and initial 
conditions were used for each. The solution was computed using a direct (UMFPACK) solver. 
Time stepping occurred from 0 to 432000 seconds (5 days) with a relative tolerance of 0.01 and 
an absolute tolerance of 0.0010. Solutions were stored for every 500 seconds. These low 
tolerances were required for the fast-changing velocity profile at the tip of the catheter near the 
start of the simulation. 
  The mesh selected for obtaining the final solution is presented in Figure 13 below. This 
free mesh was defined to have a high density of mesh elements near the catheter tip, where 
change in velocity occurs most rapidly. The mesh has a total of 3392 mesh elements with a 
minimum quality of 0.7219. To test the convergence of this mesh, several other meshes were 
solved, with a varying number of mesh elements, and the average tumor drug concentration was 
compared. The results of this analysis are shown in Figure 14 below, where it is apparent that 
with this mesh size, the mesh has converged to a single solution. 
 
   
  Figure 13: Mesh. Mesh used for model.     18 
 
 
   
  Figure 14: Mesh Convergence. Shows solution dependence on mesh. 
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Appendix C: Additional Figures 
 
  No additional figures are provided.       20 
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